


Featured Speaker Series

Insight into
who is speaking,
what they will be presenting, &
why you should be there.

» [View all speakers](#)



Robert Stockman, MBA
CEO, Chairman
REVA Medical

It's About the Money..Financing approaches to underwrite bold ideas

At the **NJ Symposium on Biomaterials Science** on **November 9, 2015**, Robert Stockman, co-founder, Chairman and CEO of REVA Medical will discuss the funding opportunities and challenges experienced by REVA on it's path from concept to product.

REVA Medical was established in 1999 to develop a revolutionary coronary stent to replace the use of permanent metallic stents with fully bioresorbable drug-eluting polymer stents. Coronary stents represent one of the most difficult biomechanical engineering challenges, due to their tiny size and mission critical function. Add to that a 25 year old entrenched industry that had perfected stent technology with tens of billions of dollars worth of R&D and clinical testing, it was therefore an ambitious undertaking to raise the requisite capital from doubting investors, especially to design a scaffold to be both degradable and X-ray visible.

REVA Medical had to progress through several innovation cycles, improving both the polymer used for making the stent and stent design and before starting clinical studies that turned out to be rife with setbacks. Many competitive companies - from the very largest such as Johnson & Johnson and Medtronic, to numerous entrepreneurial startup efforts such as REVA - failed in their efforts to invent and clinically evaluate the degradable drug-eluting coronary stent, considered the Holy Grail of cardiology. But a focus on the mission and persistence across many financing sources around the world provided REVA with the ability to raise more than \$200 million over a decade and a half. The financing success of REVA has become legend, and with some further progress and luck, the company's novel *Fantom* scaffold could also become legend.

Robert Stockman is the co-founder, Chairman and CEO of REVA Medical. Founded in 1998, REVA Medical, Inc. is dedicated to developing minimally invasive medical devices such as the development of drug-eluting bioresorbable coronary stents for the treatment of cardiovascular disease, the leading cause of death worldwide. Prior to founding REVA, Mr. Stockman previously served on the board of ZELTIQ Aesthetics, Inc., a medical technology company listed on NASDAQ until 2012. Since 1999, Mr. Stockman has been the President and Chief Executive Officer of Group Outcome LLC, a U.S.-based merchant banking firm that deploys its capital and that of its financial partners in private equity and venture capital investments in medical technology companies. Mr. Stockman also co-founded Centrimed, Inc., an internet-based software company, that was acquired by the Global Healthcare Exchange, LLC, and led the buyouts of Ioptex, an intraocular lens

manufacturer, and two Johnson & Johnson divestitures, "A" Company Orthodontics, Inc. and Critikon Company, LLC, each of which was subsequently acquired.

Mr. Stockman holds a Bachelor's Degree from Harvard College and an MBA from The Tuck School at Dartmouth College, where he serves on Tuck's Board of Overseers.

By attending the **[NJ Symposium on Biomaterials Science](#)**, not only will you hear from of the foremost experts in the biomedical/biomaterials field, but also from executive leaders and financial managers about the challenges and opportunities in funding medical device startups.

Sign Up Today

Stay Connected    

NJ Center for Biomaterials | cbmfrontdesk@dls.rutgers.edu | <http://www.njbiomaterials.org/>

145 Bevier Rd
Suite 101
Piscataway, NJ 08854